SERUM ANTI-ZONA PELLUCIDA ANTIBODIES IS CORRELATED WITH ESTRADIOL LEVEL IN WOMEN WITH IN VITRO FERTILIZATION FAILURE
Keywords:
Keywords, In vitro fertilization, Estradiol, Anti-zonapellucida antibodiesAbstract
Objective: In vitro fertilization (IVF) is one of the several assisted reproductive technologies (ART) used to aid infertile couples to conceive a child. Many factors affecting the rate of success of IVF cycle. The aim of the present study was to assess the correlation of the presence of anti-zona pellucida antibodies (AZPA) and the outcome of IVF. AZPA also was correlated with hormone levels in women with IVF failure.
Methods: Sixty women undergo IVF were participated in the study. Women group that had conceived from IVF are expressed as "pregnant group" while women who hadn't are expressed as "failure group". All groups had treatment regimen depending on parameters. Women with IVF failure were devided into subgroups according to the total gonadotrophin dosage, duration of treatment, and oocyte yield.
Results: Results revealed  that there is the insignificant difference between pregnant and failure groups in serum AZPA level. The results showed a significant higher estradiol (E2) (p=0.024), anti-müllerian (AMH) (p=0.006), and lower prolactin (PRL) (p=0.002) in pregnant in comparing with failure group. Correlations studies indicated a significant correlation between AZPA and AMH in pregnant group, and there is a significant correlation between AZPA and E2 hormone in the failure group.
Conclusion: It can be concluded that serum AZPA level does not differ between women who had success or failure IVF. However, in women with failure pregnancy in IVF, AZPA is positively correlated with E2 and its negatively correlated with PRL. In pregnant group, AZPA is positively correlated with AMH.
Keywords: In vitro fertilization, Estradiol, Anti-zonapellucida antibodies
Downloads
References
Cooper TG, Noonan E, Von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World health organization reference values for human semen characteristics. Hum Reprod 2010;16:231-45.
Olooto WE, Ambali AA, Banjo TA. A review of female infertility: important etiological factors and management. J Microbiol Biotechnol Res 2012;2:379-85.
Legro RS. A 27-year-old woman with a diagnosis of polycystic ovary syndrome. JAMA 2007;297:509-19.
Luciano AA, Lanzone A, Goverde AJ. Management of female infertility from hormonal causes. Int J Gynecol Obstet 2013;123 Suppl 2:S9-17.
Fertility: Assessment and treatment for people with fertility problems. NICE Clinical Guideline: Issued; 2013. p. 31-2.
Rani K, Paliwal S. A Brief review on in vitro fertilization (IVF): an advanced and miraculous gateway for infertility treatments. Int J Pharm Sci 2014;3:647-58.
Conner SJ, Lefièvre L, Hughes DC, Barratt CL. Cracking the egg: Increased complexity in the zona pellucida. Hum Reprod 2005;20:1148–52.
Gupta SK. Role of zona pellucida glycoproteins during fertilization in humans. J Reprod Immunol 2015;108:90-7.
Hodson D, Townsend J, Tortonese D. Characterization of the effects of prolactin in gonadotroph target cells. Biol Reprod 2010;83:1046-55.
Kostrzak A, Meczekalski B. Macroprolactinaemia. Pol Merkuriusz Lek 2010;29:47-9.
Bushe C, Bradley A, Pendlebury J. A review of hyperprolactinemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem 2010;47:292-300.
Kalsum A, Jalali S. Role of hyperprolactinemia infertility. Pakistan J Med Res 2002;41:94-100.
Muzii L, Di Tucci C, Di Feliciantonio M, Marchetti C, Perniola G, Panici PB. The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. Hum Reprod 2014;29:2190-8.
Celik HG, Dogan E, Okyay E, Uukus C, Saatli B, Uysal S, et al. Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimüllerian hormone levels. Fertil Steril 2012;97:1472-8.
Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002;77:1170-7.
Robert JN. Fertility testing. Australian Prescriber 2002;25:38-44.
Fatemi H, Kyrou D, Bourgain, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: the spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril 2010;94:2054-8.
Melo MA, Meseguer M, Garrido N. The signiï¬cance of premature luteinization in an oocyte donation programme. Hum Reprod 2006;21:1503-7.
Polotsky AJ, Daif JL, Jindal S, Lieman HJ, Santoro N, Pal L. Serum progesterone on the day of human chorionic gonadotropin administration predicts clinical pregnancy of sibling frozen embryos. Fertil Steril 2009;92:1880-5.
Shapiro BS, Daneshm ST, Garner FC, Aguirre M, Hudson C, Thomas S. Embryo cryopreservation rescues cycles with premature luteinization. Fertil Steril 2010;93:636-1.
Nawroth F, Ludwig M. What is the ‘ideal’ duration of progesterone supplementation before the transfer of cryopreserved-thawed embryos in estrogen/progesterone replacement protocols? Hum Reprod 2005;20:1127-34.
Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Contrasting patterns in in vitro fertilization pregnancy rates among fresh autologous, fresh oocyte donor, and cryopreserved cycles with the use of Day 5 or Day 6 blastocysts may reflect differences in embryo–endometrium synchrony. Fertil Steril 2008;89:20-6.
DiLuigi AJ, Nulsen JC. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function. Curr Opin Obestet Gynecol 2007;19:258-65.
Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin releasing hormone antagonists. Fertil Steril 2004;82:102-7.
Hendriks DJ, Klinkert ER, Bancsi LF, Looman CW, Habbema JD, Velde ER, et al. Use of simulated serum estradiol measurements for the prediction of hyper-response to ovarian stimulation in in vitro fertilization (IVF). J Assist Reprod Genet 2004;21:65-72.
Nelson S, Anderson R, Broekmans F, Raine-Fenning N, Fleming R, La Marca A. Anti-müllerian hormone: clairvoyance or crystal clear? Hum Reprod 2012;27:631-6.
Wunder DM, Guibourdenche J, Birkhauser MH, Bersinger NA. Anti-Mullerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/ intracytoplasmic sperm injection. Fertil Steril 2008; 90:2203-10.
Barad DH, Weghofer A, Gleicher N. Comparing anti-müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril 2009;91 Suppl 4:S1553-5.
Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23:160-7.
Smeenk JM, Sweep FC, Zielhuis GA, Kremer J, Thomas C, Braat D. Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril 2007;87:223-6.